Oncolytics Biotech Inc.
Toronto Stock Exchange ONC.TO
Oncolytics Biotech Inc. Net Income for the year ending December 31, 2023: USD -20.94 M
-
Oncolytics Biotech Inc. Net Income for the year ending December 31, 2022 was USD -18.32 M, a 11.90% change year over year.
-
Oncolytics Biotech Inc. Net Income for the year ending December 31, 2021 was USD -20.80 M, a -35.54% change year over year.
-
Oncolytics Biotech Inc. Net Income for the year ending December 31, 2020 was USD -15.34 M, a 56.22% change year over year.
-
Oncolytics Biotech Inc. Net Income for the year ending December 31, 2019 was USD -35.05 M, a -180.72% change year over year.
| Date | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) | Net Income Margin |
|---|
| CEO | Mr. Wayne F. Pisano M.B.A. |
| IPO Date | June 1, 2000 |
| Location | Canada |
| Headquarters | 322 11th Avenue SW |
| Employees | 29 |
| Sector | Health Care |
| Industries | |
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Past 5 years
USD 1.71
StockViz Staff
January 15, 2025
Any question? Send us an email